摘要
慢性丙型肝炎(chronic hepatitis C,HCV)感染可导致严重的肝病,包括肝硬化及肝癌。近年来HCV的治疗取得了突破性进展,口服直接抗病毒药物(direct-acting antiviral agents,DAAs)具有较高的抗病毒活性及良好的安全性和耐受性。HCV有3个主要的治疗靶点:NS3/4A蛋白酶,NS5B聚合酶和NS5A复制复合体。DAAs治疗方案的选择需要考虑HCV基因型、初治还是既往治疗失败、有无肝硬化以及合并的基础疾病等因素。本文介绍DAAs的临床应用方案以及在特殊人群中的应用。
HCV infection is associated with severe hepatic diseases including hepatic cirrhosis and hepatocellular carcinoma.Recent advances in the treatment of chronic hepatitis C have been achieved through the development of direct-acting antiviral agents（ DAAs）. HCV has three main therapeutic targets： the NS3/4A protease,NS5 B polymerase,and NS5 A replication complex.These agents exhibit high efficacy,improving safety and tolerability. The choice of DAAs may involve the consideration of HCV genotype,HCV treatment-naive or HCV treatment-experienced,paitents with or without cirrhosis,combined underlying diseases,etc. Pertinent clinical data and the clinical application in special HCV populations are reviewed for DAAs.
出处
《实用医院临床杂志》
2016年第2期23-29,共7页
Practical Journal of Clinical Medicine
关键词
慢性丙型肝炎
直接抗病毒药物
蛋白酶抑制剂
聚合酶抑制剂
Chronic hepatitis C
Direct acting antiviral agents
Protease inhibitors
Polymerase inhibitors
